

Nayana Gaur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1367295/publications.pdf>

Version: 2024-02-01

14
papers

274
citations

933447

10
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

479
citing authors

#	ARTICLE	IF	CITATIONS
1	Reaction to Endoplasmic Reticulum Stress via ATF6 in Amyotrophic Lateral Sclerosis Deteriorates With Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 5.	3.4	49
2	Plasma VCAM1 levels correlate with disease severity in Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 94.	7.2	37
3	The 5-Hydroxytryptamine signaling map: an overview of serotonin-serotonin receptor mediated signaling network. <i>Journal of Cell Communication and Signaling</i> , 2018, 12, 731-735.	3.4	30
4	The Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis: Signals From the CNS and Beyond. <i>Frontiers in Neurology</i> , 2020, 11, 377.	2.4	25
5	Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model. <i>Frontiers in Neuroscience</i> , 2021, 15, 651651.	2.8	24
6	Applying the D50 disease progression model to gray and white matter pathology in amyotrophic lateral sclerosis. <i>NeuroImage: Clinical</i> , 2020, 25, 102094.	2.7	19
7	Disease progression impacts health-related quality of life in amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 2019, 397, 92-95.	0.6	17
8	Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the D50 disease progression model. <i>Human Brain Mapping</i> , 2021, 42, 737-752.	3.6	16
9	Modelling disease course in amyotrophic lateral Sclerosis: pseudo-longitudinal insights from cross-sectional health-related quality of life data. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 117.	2.4	14
10	Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis. <i>NeuroImage: Clinical</i> , 2021, 30, 102674.	2.7	12
11	Blood-Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral Sclerosis. <i>Frontiers in Neuroscience</i> , 2021, 15, 656456.	2.8	11
12	Developing a Neuroimaging Biomarker for Amyotrophic Lateral Sclerosis: Multi-Center Data Sharing and the Road to a "Global Cohort". <i>Frontiers in Neurology</i> , 2018, 9, 1055.	2.4	10
13	Triage of Amyotrophic Lateral Sclerosis Patients during the COVID-19 Pandemic: An Application of the D50 Model. <i>Journal of Clinical Medicine</i> , 2020, 9, 2873.	2.4	6
14	Age- and airway disease related gene expression patterns of key SARS-CoV-2 entry factors in human nasal epithelia. <i>Virology</i> , 2021, 561, 65-68.	2.4	4